Commentary

Predicting Treatment Outcomes: The Case for Hypoxia Gene Signatures

Laure Marignol *

Translational Radiobiology and Oncology, Applied Radiation Therapy Trinity, Discipline of Radiation Therapy and Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland

Prostate cancer affects a large number of men worldwide: over a million new cases were diagnosed in 2012 (~320,000 in Europe) [1]. The recognised changes in demography (aging) and lifestyle (obesity) of the male population are predicted to give rise to an increase in the incidence of prostate cancer [2]. It is estimated that approximately one in eight men will be diagnosed with prostate cancer and will therefore have to make a choice regarding the best course of treatment of their disease. Most of these men will be candidates for curative treatment with either radical surgery or radiation therapy (external beam, brachytherapy).

Today the selection of a treatment plan for a particular prostate cancer patient is driven by clinical and pathological features defining spectrums of local recurrence risk. The assessment of the risk of recurrence and subsequent prostate-cancer specific mortality is based on a measure of the prostate specific antigen (PSA) level in a blood sample, the scoring of biopsy specimens by a pathologist (Gleason scores) and the estimation of tumour extent within (T) and outside the prostate (regional lymph nodes (N), distant metastases (M)) [3]. This risk classification system is however now challenged, as it is unable to adequately assess the variability in the aggressiveness of newly diagnosed prostate cancer. Personalized medicine through the integration of tumour-specific biological parameters into the decision-making process is anticipated to overcome these challenges and alter the management of prostate cancer patients.

The molecular classification of prostate cancer with microarray and next generation sequencing technologies is under way. Differential analyses of extensive genetic profiles of specimens, using advanced statistical classification methods, such as cluster analysis, have progressed the use of genetic signatures from tumour tissue in providing additional prognostic information [4].

A common feature of solid tumours, including the prostate, the chaotic development of the tumour vasculature compromises the efficient spatial and functional delivery of blood supply to cancer cells. The presence of these hypoxic regions is well recognised as a cause for genomic instability, disease progression and treatment resistance [5]. As a result exploiting hypoxia as a classifier for the molecular characterisation of cancer is an attractive strategy and several molecular signatures have been defined [6–8]. But deriving these signatures requires a stringent work flow that often starts in vitro, involves large training and validation patient cohorts and complex computational and statistical tools. In their study, published in EBioMedicine, Yang et al. began their analysis in four prostate cancer cell lines and identified 848 genes whose expression was modified under hypoxic conditions [9]. Hypothesising that the in vitro genes co-expressing with each other in vivo collectively indicate hypoxia, the authors leveraged the TCGA cohort of pre-treatment biopsies to construct an extensive co-expression network and identified 28 hypoxia-regulated genes associated with prognostic outcome. Perhaps reassuring is that ten of these genes were previously reported hypoxia regulated genes.

The personalisation of prostate cancer management relies on the discovery of novel biomarkers predictive of treatment outcomes. This 28-gene signature presents a major step in this direction. Evaluated in both fresh frozen and formalin-fixed–paraffin embedded (FFPE) biopsy specimen, the implementation of this signature in clinical practice should be relatively easy. Its ability to predict biochemical failure following both radical prostatectomy and radiation therapy as well as distant metastasis outcomes will benefit the vast majority of prostate cancer patients. Although associated with a number of outstanding challenges, such as the robustness of the signature in a prospective hypoxia-modifying prostate cancer clinical trial, the stability of these 28 genes across the heterogeneous and ever-changing oxygenation levels of prostate tumours [10], further evaluation of hypoxia signatures as a tool to predicting treatment outcomes in prostate cancer is certainly warranted.

Disclosure

The author declared no conflicts of interest.

References

1 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359–86.
2 Möller H, Fairley L, Coupland V, Okello C, Green M, Forman D, et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer 2007;96(9):1484–8.
3 Möller J, Bahinson RR, Boston B, Rusby JE, D’Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8(2):162–200.
4 Bristow RG, Berlin A, Dal Pra A. An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy. Br J Radiol 2014;87(1035):20130753.
5 Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 2008;34(4):313–27.
6 Jonsson M, Ragnar HB, Jutilin CH, Yeramian A, Clancy T, Frikstad KM, et al. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. Br J Cancer 2016;115(8):529–39.

* Corresponding author.
E-mail address: marignl@tcd.ie.

https://doi.org/10.1016/j.ebiom.2018.05.016
2352-3964/© 2018 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
7 Dey P, Velazquez-Villegas LA, Faria M, Turner A, Jonsson P, Webb P, et al. Estrogen receptor beta2 induces hypoxia signature of gene expression by stabilizing HIF-1alpha in prostate cancer. PLoS ONE 2015;10(5):e0128239.
8 Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol 2014;15(13):1521–32.
9 Yang L, Roberts D, Takhar M, et al. Development and validation of a 28-gene hypoxia-related prognostic signature for localized prostate cancer. EBioMedicine 2018. https://doi.org/10.1016/j.ebiom.2018.04.019.
10 Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58(3):730–7.